Mass General Brigham investigators approved for large studies on reversing acute suicidal depressed state, bipolar depression

Research teams at Mass General Brigham’s founding members, Brigham and Women’s Hospital (BWH) and Massachusetts General Hospital (MGH), have been approved for more than $50 million in funding awards by the Patient-Centered Outcomes Research Institute (PCORI) for studies focused on treating two important mental health conditions. Both projects are large-scale, high-impact research trials that will invite patients to participate at sites throughout the country, including at MGH, Brigham and Women’s Faulkner Hospital (BWFH), and McLean Hospital, all members of the Mass General Brigham system.

The team at MGH, led by Andrew A. Nierenberg, MD, director of the Dauten Family Center for Bipolar Treatment Innovation, and Andrea S. Foulkes, ScD, director of Biostatistics, will use their nearly $25 million in funding to compare the effectiveness of four treatments for bipolar depression.

For more information, see: